|
Title
|
|
|
|
New-generation drug-eluting stents : focus on Xience V® everolimus-eluting stent and Resolute® zotarolimus-eluting stent
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Compared to bare metal stent angioplasty, first-generation drug-eluting stents (DES) have markedly reduced the incidence of in-stent restenosis. However, given the increased concerns over late and very late stent thrombosis, newer-generation DES were developed. To date, these DES have virtually replaced the use of first-generation DES worldwide. In this review article, we carefully consider the pre-clinical and clinical trials that have been performed with currently available, european conformity-marked and Food and Drug Administration-approved new-generation Resolute (R) and Xience V (R) DES. (J Interven Cardiol 2013;26:278-286) |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Journal of interventional cardiology. - Mount Kisco, N.Y.
|
|
|
Publication
|
|
|
|
Mount Kisco, N.Y.
:
2013
|
|
|
ISSN
|
|
|
|
0896-4327
1540-8183
|
|
|
DOI
|
|
|
|
10.1111/JOIC.12028
|
|
|
Volume/pages
|
|
|
|
26
:3
(2013)
, p. 278-286
|
|
|
ISI
|
|
|
|
000320173700010
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|